Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cambridge Nutritional SciencesFRA:RVKA Net-Net Working Capital is €0.02 as of Sep. 2025. The stock has 3 warning signs investors should review. Among 420 Medical Devices & Instruments companies, Cambridge Nutritional Sciences ranks better than 97.62% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
The industry rank for Cambridge Nutritional Sciences's Net-Net Working Capital or its related term are showing as below:
FRA:RVKA's Price-to-Net-Net-Working-Capital is ranked better than 97.62% of 420
companies
in the Medical Devices & Instruments industry
Industry Median: 6.825
vs FRA:RVKA: 0.73
Cambridge Nutritional Sciences (FRA:RVKA) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Cambridge Nutritional Sciences Net-Net Working Capital Related Terms
Cambridge Nutritional Sciences Net-Net Working Capital Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cambridge Nutritional Sciences Net-Net Working Capital Chart
FRA:RVKA vs ISRG, BDX, MDLN: Net-Net Working Capital Comparison
For the Medical Instruments & Supplies subindustry, Cambridge Nutritional Sciences's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cambridge Nutritional Sciences Price-to-Net-Net-Working-Capital vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cambridge Nutritional Sciences's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Cambridge Nutritional Sciences's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of €0.02 mean?
Cambridge Nutritional Sciences (FRA:RVKA) has a Net-Net Working Capital of €0.02 as of Sep. 2025. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Cambridge Nutritional Sciences According to the industry distribution chart, Cambridge Nutritional Sciences ranks #10 out of 420 companies in the Medical Devices & Instruments industry, placing it in the top 2.4%.
Is Cambridge Nutritional Sciences' Net-Net Working Capital too high?
Cambridge Nutritional Sciences' current Net-Net Working Capital is €0.02. Based on the distribution chart, Cambridge Nutritional Sciences ranks #10 out of 420 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Cambridge Nutritional Sciences' Net-Net Working Capital compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Cambridge Nutritional Sciences ranks #10 out of 420 companies for Net-Net Working Capital. This places Cambridge Nutritional Sciences in the top 2% of its industry — outperforming the majority of peers. The industry median Net-Net Working Capital is 6.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Medical Devices & Instruments company?
The median Net-Net Working Capital among Medical Devices & Instruments companies is 6.83, based on 420 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Cambridge Nutritional Sciences For the Medical Devices & Instruments industry, the median Net-Net Working Capital is 6.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cambridge Nutritional Sciences's current Net-Net Working Capital is €0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambridge Nutritional Sciences stock overvalued right now?
Based on GuruFocus' analysis, Cambridge Nutritional Sciences (FRA:RVKA) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.02, compared to a current price of €0.01 — trading 27.5% below its estimated fair value. The current Net-Net Working Capital is €0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Cambridge Nutritional Sciences (FRA:RVKA), the current Net-Net Working Capital is €0.02 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cambridge Nutritional Sciences PLC is a medical diagnostics company specializing in the development, manufacture, and distribution of food sensitivity test kits. Its product portfolio includes tests designed to detect immune reactions to various foods, helping healthcare professionals and patients identify dietary and lifestyle changes to improve long-term health and wellbeing. The company operates in the United Kingdom and serves the customer base across various countries through laboratories and healthcare providers. It generates revenue by selling diagnostic kits and providing clinical analysis services centered on food sensitivity and gut health. The group has two reportable segments: Health and Nutrition; and Corporate. The Health and Nutrition segment generates majority revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RVKA has been successfully added to your 
